- $12.37m
- $80.26m
- $30.26m
- 35
- 80
- 12
- 37
R2019 December 31st | R2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K/A | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 15.6 | 15.4 | 20.3 | 47.3 | 30.3 |
Cost of Revenue | |||||
Gross Profit | 5.21 | 4.36 | 5.88 | 7.06 | 3.61 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 18.2 | 26.2 | 43.7 | 111 | 90.9 |
Operating Profit | -2.62 | -10.8 | -23.4 | -63.6 | -60.7 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.72 | 0.286 | -40.2 | -69.5 | -97.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.6 | 2.06 | -36.2 | -69.7 | -97.5 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -2.89 | 1.9 | -33.1 | -59.8 | -80.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.89 | 1.9 | -33.1 | -59.8 | -80.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -61 | 7.1 | -13.7 | -8.78 | -7.76 |